检索
AI 对话
AI 辅写
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Imatinib (IM) in combination with Hydroxyurea in patients with CML1st CP does not increase molecular response at 18 months compared to IM alone. Final results of the OSHO CML2004 study. NCT 02480608

Thoralf Lange,R. Krahl, U. von Grünhagen,H. K. Al-Ali,A. Schwarzer,K. Jentsch-Ullrich, C. Spohn,V. Lakner,M. Assmann,C. Junghanss,M. Pfirrmann,A. Gil, R. Hehlmann,Michael W. Deininger,Dietger Niederwieser

ONCOLOGY RESEARCH AND TREATMENT（2017）

引用 23|浏览31
暂无评分
关键词
cml1st cp,hydroxyurea,osho cml2004 study
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要